Description
The Practice of Medicinal Chemistry, Fourth Edition provides a practical and comprehensive overview of the daily issues facing pharmaceutical researchers and chemists. In addition to its thorough treatment of basic medicinal chemistry principles, this updated edition has been revised to provide new and expanded coverage of the latest technologies and approaches in drug discovery. With topics like high content screening, scoring, docking, binding free energy calculations, polypharmacology, QSAR, chemical collections and databases, and much more, this book is the go-to reference for all academic and pharmaceutical researchers who need a complete understanding of medicinal chemistry and its application to drug discovery and development.
Nicknamed "The Bible" by medicinal chemists shortly after the first edition was published in 1996, this updated text provides a comprehensive overview of the daily issues facing medicinal chemists and pharmaceutical researchers
About the Author
Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d'Etudes Physio-biologiques Appliquees a la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine. Professor Wermuths' main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome. Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Societe Francaise de Chimie Therapeutique, the Leon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.
Reviews
"...So that you are a young student of a faculty in the field of pharmacology looking for a formative text, a young researcher at the beginning of his or her experiential work or an expert in the "drug discovery" industry that only wants to deepen theme specifications, most likely in this book you will find what you need." (Google translation) --La Chimica e l'Industria "...provides a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences." --Drug Development Research Praise for the Third Edition: "The third edition of this book, useful to seasoned medicinal chemists as well as to chemists entering the academic or industrial laboratories, provides a hands-on overview of the drug discovery process. This edition differs from the previous two editions by having been updated to reflect developments in the past 5 years, and it includes 11 new chapters. I found this book to be unique, well organized, and overall a useful addition to the medicinal chemistry literature. Having favorably reviewed the first edition, I still highly recommend this third edition to all chemists who are involved in the drug discovery process." --John L. Neumeyer, Harvard Medical School, Journal of Medicinal Chemistry "...a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences."--Drug Development Research
Book Information
ISBN 9780124172050
Author Camille Georges Wermuth
Format Hardback
Page Count 902
Imprint Academic Press Inc
Publisher Elsevier Science Publishing Co Inc
Weight(grams) 2560g
Nicknamed "The Bible" by medicinal chemists shortly after the first edition was published in 1996, this updated text provides a comprehensive overview of the daily issues facing medicinal chemists and pharmaceutical researchers
About the Author
Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d'Etudes Physio-biologiques Appliquees a la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine. Professor Wermuths' main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome. Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Societe Francaise de Chimie Therapeutique, the Leon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.
Reviews
"...So that you are a young student of a faculty in the field of pharmacology looking for a formative text, a young researcher at the beginning of his or her experiential work or an expert in the "drug discovery" industry that only wants to deepen theme specifications, most likely in this book you will find what you need." (Google translation) --La Chimica e l'Industria "...provides a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences." --Drug Development Research Praise for the Third Edition: "The third edition of this book, useful to seasoned medicinal chemists as well as to chemists entering the academic or industrial laboratories, provides a hands-on overview of the drug discovery process. This edition differs from the previous two editions by having been updated to reflect developments in the past 5 years, and it includes 11 new chapters. I found this book to be unique, well organized, and overall a useful addition to the medicinal chemistry literature. Having favorably reviewed the first edition, I still highly recommend this third edition to all chemists who are involved in the drug discovery process." --John L. Neumeyer, Harvard Medical School, Journal of Medicinal Chemistry "...a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences."--Drug Development Research
Book Information
ISBN 9780124172050
Author Camille Georges Wermuth
Format Hardback
Page Count 902
Imprint Academic Press Inc
Publisher Elsevier Science Publishing Co Inc
Weight(grams) 2560g
